Videos

Stroke recurrence risk peaks in the first days after TIA or minor stroke, driving rapid evaluation and tailored prevention strategies like short-term dual antiplatelet therapy.

The senior research investigator at the New York Stem Cell Foundation answered questions about the research efforts needed to advance iPSC human models toward clinical relevance for patients with multiple sclerosis. [WATCH TIME: 4 minutes]

A duo of neuro-oncologists from Northwestern Medicine explained how to distinguish paraneoplastic neurologic syndromes from treatment toxicity and metastatic disease. [WATCH TIME: 8 minutes]

The head of the Phase I Clinical Research Unit at Beijing Tiantan Hospital discussed positive clinical trial findings for a dual-target neuroprotectant in patients with acute ischemic stroke presented at ISC 2026. [WATCH TIME: 3 minutes]

The professor of medicine at McMaster University discussed findings from OCEANIC-STROKE, where treatment with asundexian reduced the risk of recurrent stroke without increasing major hemorrhage in patients. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending February 21, 2026. [WATCH TIME: 5 minutes]

An associate professor in neurosurgery at Duke University discussed his presentation on novel meningeal immune interactions and interferon signaling in multiple sclerosis at the ACTRIMS Forum 2026. [WATCH TIME: 3 minutes]

Clinicians discuss distinguishing between true progression and pseudo-relapses in MS, emphasizing patient insights and monitoring changes over time.

Experts discuss identifying early signs of disease progression through patient history, symptoms, and innovative monitoring techniques for better care.

A movement disorder specialist at Northwestern Medicine discussed developments in disease-modifying research, adaptive clinical trial designs, and evolving device-based therapies in Parkinson disease. [WATCH TIME: 5 minutes]

The chief medical advisor at the Muscular Dystrophy Association also discussed what he personally is looking forward to at the conference this year. [WATCH TIME: 4 minutes]

A pediatric neurologist at the UCL Institute of Neurology in London, England discussed how pediatric-onset MS is marked by intense inflammation, unique neurodevelopmental considerations, and evolving treatment paradigms at ACTRIMS 2026. [WATCH TIME: 5 minutes]

Experts unpack stroke recurrence disparities, AHA prevention tactics, lifestyle essentials, and emerging factor XIa inhibitors shaping future care.

Neurology experts highlighted ongoing developments in artificial intelligence applications, disease-modifying mechanisms, and genetic therapies expected to undergo evaluation. [WATCH TIME: 9 minutes]

Panelists share tailored stroke recurrence prevention: control BP, lipids, and lifestyle, address disparities, and weigh factor XIa inhibitors.

Andrew Russman, DO, director of Cleveland Clinic’s Comprehensive Stroke Center, provided an analysis of the phase 3 OCEANIC-STROKE data of asundexian in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack.

A professor of neurology from the University of Barcelona discussed the clinical implications of adding intra-arterial alteplase after thrombectomy in patients with Large-vessel occlusion (LVO) acute ischemic stroke at ISC 2026.

The director of the clinical neuroimmunology fellowship at Cleveland Clinic discussed the evolving clinical trial landscape of hematopoietic stem cell transplantation and other cell-based therapies in multiple sclerosis. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending February 14, 2026. [WATCH TIME: 4 minutes]

The professor of neurology at the University of Alabama at Birmingham talked about findings from a CREST-2 substudy presented at ISC 2026 showing that revascularization did not improve cognitive outcomes in patients with asymptomatic carotid artery disease. [WATCH TIME: 5 minutes]

Experts discuss the impact of genetic, lifestyle, and environmental factors on multiple sclerosis progression and disability management.

A duo of experts at ISC 2026 discussed results from a clinical trial of high-dose, home-based constraint-induced movement therapy in infants with perinatal arterial ischemic stroke. [WATCH TIME: 5 minutes]

Explore the complexities of disease biology, focusing on relapsing and progressive mechanisms that impact treatment and patient outcomes.

The Allen Geller distinguished professor of immunology at Duke University School of Medicine discusses the connection between Epstein Barr Virus and Multiple Sclerosis, citing decades of research that position EBV as a leading environmental risk factor and a potential therapeutic target in MS. [WATCH TIME: 4 minutes]

The assistant professor of medicine at the University of Toronto discussed whether multiple sclerosis can develop prior to Epstein–Barr virus infection and what new population data reveal about the long-standing causality debate. [WATCH TIME: 4 minutes]

Joseph Sullivan, MD, talked about the importance of understanding the underlying etiology of LGS and revisiting treatment strategies as patients transition to adulthood.

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis provided background on a study presented at ACTRIMS 2026 focused on patient-reported barriers to timely multiple sclerosis treatment initiation. [WATCH TIME: 4 minutes]

The associate professor of neurology at the University of California, San Francisco discussed the evolving approach to remyelination in patients with MS at the 2026 ACTRIMS Forum. [WATCH TIME: 3 minutes]

The professor of neurology at Cleveland Clinic discussed how evolving imaging and biological insights have reshaped the way clinicians define and talk about multiple sclerosis. [WATCH TIME: 3 minutes]

The senior research investigator at the New York Stem Cell Foundation discussed how human iPSC-based models can help dissect the cellular mechanisms underlying PIRA and progressive disability in multiple sclerosis. [WATCH TIME: 3 minutes]